Shares of Moderna fell 2.39% to $98.62 at 15:08 EST on Tuesday, after three consecutive sessions in a row of gains. The Nasdaq Stock Market is rising 1.16% to $12,018.20, following yesterday’s upward trend, on what up until now seems, an all-around positive trend trading session today.
According to yesterday’s article on Bloomberg Quint, “Moderna Chief Sells More Shares Ahead of Urgent Vaccine Filing.”
Moderna’s last close was $101.03, below its 52-week high of $103.20.
Moderna’s sales growth is 1195.8% for the ongoing quarter and 5174.8% for the next. The company’s growth estimates for the current quarter is a negative 67.6% and positive 254.3% for the next.
Year-on-year quarterly revenue growth grew by 826.4%, now sitting on 246.7M for the twelve trailing months.
Moderna’s stock is valued at $98.62 at 15:08 EST, under its 52-week high of $103.20 and way above its 52-week low of $17.68.
Moderna’s worth is way above its 50-day moving average of $77.03 and way above its 200-day moving average of $69.89.
According to Bloomberg Quint on Fri Nov 20, “EU Could Approve BioNTech, Moderna Vaccines in December.”